Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa crossover study of inhaled AZD8871 in moderate to severe COPD
2016-002863-32Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navafenterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in trough FEV1 on Day 15. Started Oct 2016; status: completed.
02
Drugs
navafenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-002863-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002863-32.